» Articles » PMID: 34529659

Trends in the Prevalence of Microscopically-confirmed Schistosomiasis in the South African Public Health Sector, 2011-2018

Overview
Date 2021 Sep 16
PMID 34529659
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Schistosomiasis, also known as bilharzia, is a chronic parasitic blood fluke infection acquired through contact with contaminated surface water. The illness may be mild or can cause significant morbidity with potentially serious complications. Children and those living in rural areas with limited access to piped water and services for healthcare are the most commonly infected. To address the prevalence of the disease in parts of South Africa (SA) effective national control measures are planned, but have not yet been implemented. This study aimed to estimate the prevalence and trends of public sector laboratory-confirmed schistosomiasis cases in SA over an eight-year (2011-2018) period, to inform future control measures.

Methodology & Principal Findings: This is a descriptive analysis of secondary data from the National Health Laboratory Service (NHLS). The study included all records of patients for whom microscopic examination detected Schistosoma species eggs in urine or stool specimens from January 2011 to December 2018. Crude estimates of the prevalence were calculated using national census mid-year provincial population estimates as denominators, and simple linear regression was used to analyse prevalence trends. A test rate ratio was developed to describe variations in testing volumes among different groups and to adjust prevalence estimates for testing variations. A total number of 135 627 schistosomiasis cases was analysed with the highest prevalence observed among males and individuals aged 5-19 years. We describe ongoing endemicity in the Eastern Cape Province, and indicate important differences in the testing between population groups.

Conclusion: While there was no overall change in the prevalence of schistosomiasis during the analysis period, an average of 36 people per 100 000 was infected annually. As such, this represents an opportunity to control the disease and improve quality of life of affected people. Laboratory-based surveillance is a useful method for reporting occurrence and evaluating future intervention programs where resources to implement active surveillance are limited.

Citing Articles

Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.

Motlhatlhedi K, Pilusa N, Ndaba T, George M, Masamba P, Kappo A Am J Transl Res. 2024; 16(9):4279-4300.

PMID: 39398578 PMC: 11470331. DOI: 10.62347/BXRT7210.


Capacities and needs of health care facilities for schistosomiasis diagnosis and management in elimination settings.

Ndum N, Trippler L, Mohammed U, Ali A, Hattendorf J, Utzinger J Parasit Vectors. 2024; 17(1):263.

PMID: 38886811 PMC: 11184784. DOI: 10.1186/s13071-024-06311-8.


Predicting Schistosomiasis Intensity in Africa: A Machine Learning Approach to Evaluate the Progress of WHO Roadmap 2030.

Chen X, Le J, Hu Y Am J Trop Med Hyg. 2024; 111(1):73-79.

PMID: 38772355 PMC: 11229641. DOI: 10.4269/ajtmh.23-0751.


Evaluating the Prevalence and Risk Factors of Schistosomiasis Amongst School-Aged Children in Low- and Middle-Income Communities: Ehlanzeni District Municipality, South Africa, 2015-2021.

Njikho S, Quan V, Mbonane T, Van Wyk R Trop Med Infect Dis. 2023; 8(12).

PMID: 38133454 PMC: 10748275. DOI: 10.3390/tropicalmed8120522.


Forgotten but not gone in rural South Africa: Urinary schistosomiasis and implications for chronic kidney disease screening in endemic countries.

Craik A, Gondwe M, Mayindi N, Chipungu S, Khoza B, Gomez-Olive X Wellcome Open Res. 2023; 8:68.

PMID: 37840883 PMC: 10576187. DOI: 10.12688/wellcomeopenres.18650.3.


References
1.
Kjetland E, Leutscher P, Ndhlovu P . A review of female genital schistosomiasis. Trends Parasitol. 2012; 28(2):58-65. DOI: 10.1016/j.pt.2011.10.008. View

2.
Toor J, Alsallaq R, Truscott J, Turner H, Werkman M, Gurarie D . Are We on Our Way to Achieving the 2020 Goals for Schistosomiasis Morbidity Control Using Current World Health Organization Guidelines?. Clin Infect Dis. 2018; 66(suppl_4):S245-S252. PMC: 5982704. DOI: 10.1093/cid/ciy001. View

3.
van der Werf M, de Vlas S, Brooker S, Looman C, Nagelkerke N, Habbema J . Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003; 86(2-3):125-39. DOI: 10.1016/s0001-706x(03)00029-9. View

4.
SCHUTTE C, van Deventer J, Lamprecht T . A cross-sectional study on the prevalence and intensity of infection with Schistosoma haematobium students of Northern KwaZulu. Am J Trop Med Hyg. 1981; 30(2):364-72. DOI: 10.4269/ajtmh.1981.30.364. View

5.
Colley D, Bustinduy A, Evan Secor W, King C . Human schistosomiasis. Lancet. 2014; 383(9936):2253-64. PMC: 4672382. DOI: 10.1016/S0140-6736(13)61949-2. View